COLUMBUS, Ohio — Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases. GM2 gangliosidosis is a rare,...

TINLEY PARK, Ill. –  Hematogenix®, a global specialty laboratory and contract research organization focused on oncology and hematopathology, announced that its proprietary Next Generation Flow Cytometry  (NGF) assay for MM MRD served as the analytical method for the pivotal efficacy endpoint supporting the U.S. Food and Drug Administration’s (FDA) accelerated...

Cardiff, UK – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3...